1-3 of 3
Crystal S. Denlinger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

Ani S. Balmanoukian, Jeffrey R. Infante, Raid Aljumaily, Aung Naing, Ashish V. Chintakuntlawar, Naiyer A. Rizvi, Helen J. Ross, Michael Gordon, Philip R. Mallinder, Nairouz Elgeioushi, Ignacio González-García, Nathan Standifer, Jennifer Cann, Nicholas Durham, Shahram Rahimian, Rakesh Kumar, Crystal S. Denlinger
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (23): 6196–6203.
https://doi.org/10.1158/1078-0432.CCR-20-0452
Published: 01 December 2020
View article titled, Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
Open the PDF for Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer

Efrat Dotan, Dana B. Cardin, Heinz-Josef Lenz, Wells Messersmith, Bert O'Neil, Steven J. Cohen, Crystal S. Denlinger, Safi Shahda, Igor Astsaturov, Ann M. Kapoun, Rainer K. Brachmann, Shailaja Uttamsingh, Robert J. Stagg, Colin Weekes
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5348–5357.
https://doi.org/10.1158/1078-0432.CCR-20-0489
Published: 15 October 2020
View article titled, Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer
Open the PDF for Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer in another window
Journal Articles

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Ronan J. Kelly, Jeeyun Lee, Yung-Jue Bang, Khaldoun Almhanna, Mariela Blum-Murphy, Daniel V.T. Catenacci, Hyun Cheol Chung, Zev A. Wainberg, Michael K. Gibson, Keun-Wook Lee, Johanna C. Bendell, Crystal S. Denlinger, Cheng Ean Chee, Takeshi Omori, Rom Leidner, Heinz-Josef Lenz, Yee Chao, Marlon C. Rebelatto, Philip Z. Brohawn, Peng He, Jennifer McDevitt, Siddharth Sheth, Judson M. Englert, Geoffrey Y. Ku
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (4): 846–854.
https://doi.org/10.1158/1078-0432.CCR-19-2443
Published: 14 February 2020
View article titled, Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Open the PDF for Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma in another window
Includes: Supplementary data